SpringWorks Therapeutics, Inc acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer.
infoSpringWorks Therapeutics is a small cap stock with a total market cap of 1.78B.
infoThey trade on the NASDAQ and had their IPO 3 years and 11 months ago.
infoSpringWorks Therapeutics currently employs 227 people.
infoAs of Wednesday, Aug 23 2023, SpringWorks Therapeutics’s share price is $28.47.
News Relating to SpringWorks Therapeutics
Seeking Alpha
SpringWorks Therapeutics: FDA Decision Date Ahead
Wednesday Jul 12 2023 at 15:33
Today we revisit SpringWorks Therapeutics, Inc. for the first time in nearly a year. The company’s primary drug asset is on the cusp of garnering SpringWorks’ first FDA approval for a rare affliction. An updated investment analysis follows in the paragraphs below.
GlobeNewsWire
SpringWorks Therapeutics to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference
Wednesday Jun 07 2023 at 07:00
STAMFORD, Conn., June 07, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA on Monday, June 12, 2023 beginning at 11:20 a.m. PT / 2:20 p.m. ET.
Reuters
US FDA delays decision on SpringWorks Therapeutics’ tumor treatment
Monday Jun 05 2023 at 11:04
The U.S. Food and Drug Administration (FDA) has extended its decision for SpringWorks Therapeutics Inc’s tumor treatment by three months as the health regulator needs more time to review additional data, the company said on Monday.
Seeking Alpha
SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline
Friday Apr 14 2023 at 10:25
SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline
GlobeNewsWire
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Tuesday Jan 03 2023 at 07:00
STAMFORD, Conn., Jan. 03, 2023 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 7:30 a.m. PT.
Zacks Investment Research
Here’s Why You Should Consider Investing in JAZZ Stock Now
Monday Oct 17 2022 at 12:03
JAZZ’s new drugs like Xywav, Rylaze and Zepzelca, along with the recently-acquired drugs, are expected to generate 65% of product revenues in 2022.
Zacks Investment Research
SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma
Thursday Sep 08 2022 at 14:18
Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK’s (GSK) development program for its multiple myeloma drug, Blenrep.
GlobeNewsWire
SpringWorks Therapeutics to Present at the 2022 Wedbush PacGrow Healthcare Conference
Tuesday Aug 02 2022 at 07:00
STAMFORD, Conn., Aug. 02, 2022 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on Wednesday, August 10th at 10:55 a.m. ET.
Benzinga
SpringWorks Therapeutics Shares Jump On HC Wainwright Bullish Pitch
Monday Jun 13 2022 at 09:14
HC Wainwright points out that investors are enthusiastic about SpringWorks Therapeutics Inc (NASDAQ: SWTX) nirogacestat clinical profile for desmoid tumors after the R&D day held last week. As per a survey of U.S. oncologists treating patients with desmoid tumors, roughly 80%.
GlobeNewsWire
SpringWorks Therapeutics to Present Progress Across the Company’s Targeted Oncology Portfolio at Virtual R&D Day
Friday Jun 10 2022 at 06:30
— NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA’s Real-Time Oncology Review (RTOR) Program, Expected in Second Half of 2022 — — New Phase 2 Study Announced to Evaluate Nirogacestat in Patients with Ovarian Granulosa Cell Tumors —
GlobeNewsWire
SpringWorks Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference
Thursday Jun 09 2022 at 07:00
STAMFORD, Conn., June 09, 2022 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, CA on Wednesday, June 15th at 8:40 a.m. PT / 11:40 a.m. ET.
Invezz
Here is why SpringWorks Therapeutics jumped 20%
Friday May 27 2022 at 16:13
SpringWorks Therapeutics Inc. (NASDAQ: SWTX) stock jumped 20% after the clinical-stage company focusing on life-changing treatment for cancer, and rare diseases announced encouraging results from its DeFi study. The trial was a placebo-controlled, double-blind third phase study assessing the safety, tolerability, and efficacy of the company’s experimental oral gamma-secretase inhibitor, Nirogacestat, in the treatment of […] The post Here is why SpringWorks Therapeutics jumped 20% appeared first on Invezz.
Zacks Investment Research
SpringWorks (SWTX) Down Despite Desmoid Tumors Study Meeting Goal
Wednesday May 25 2022 at 13:48
SpringWorks’ (SWTX) phase III study evaluating its investigational candidate, nirogacestat, in adult patients with progressing desmoid tumors, meets primary and key secondary endpoints.
Market Watch
SpringWorks shares jump 14%; company plans to seek FDA approval for desmoid tumor therapy this year
Tuesday May 24 2022 at 07:39
Shares of SpringWorks Therapeutics Inc. SWTX, +2.18% were up 14.9% in premarket trading on Tuesday after the company said a late-stage clinical trial evaluating its treatment for patients with progressing desmoid tumors met its primary endpoint. A desmoid tumor is a rare disease.
Seeking Alpha
SpringWorks Therapeutics: Rating Buy Ahead Of Mid-Year Data Releases
Monday May 02 2022 at 17:42
Data from Phase 3 trial for Nirogacestat in treating desmoid tumors and Phase 2 combination trial with anti-BCMA antibody Blenrep in relapsed/refractory multiple myeloma is expected in mid-year. The company has multiple partnerships (including with Pfizer, GlaxoSmithKline, Janssen, Seattle Biosciences, Allogene, etc.) to combine Nirogacestat with their anti-BCMA therapies.
Seeking Alpha
Allogene: Speculative CAR T Biotech With Big Potential In Oncology
Friday Apr 01 2022 at 22:54
Allogene: Speculative CAR T Biotech With Big Potential In Oncology
Benzinga
Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks
Wednesday Mar 09 2022 at 12:03
Since the coronavirus pandemic began in early 2020, the FDA’s plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the back burner.
GlobeNewsWire
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
Tuesday Feb 01 2022 at 06:30
STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will present at the following upcoming investor conferences:
GlobeNewsWire
SpringWorks Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Tuesday Jan 04 2022 at 06:30
STAMFORD, Conn., Jan. 04, 2022 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 8:15 am ET.
Seeking Alpha
SpringWorks Is A Biotech To Watch With Several Partnerships And Solid Drug Pipeline
Tuesday Dec 14 2021 at 04:57
Results from the phase 3 DeFi study using Nirogacestat as a monotherapy for patients with desmoid tumors are expected to be released end of 2021 or early 2022. Nirogacestat is being explored in 7 combinations trials for the treatment of patients with multiple myeloma.
Benzinga
AbbVie, SpringWorks Join Forces To Conduct Multiple Myeloma Combo Therapy Trial
Friday Dec 10 2021 at 09:24
SpringWorks Therapeutics Inc (NASDAQ: SWTX) entered into a clinical trial collaboration agreement with AbbVie Inc (NYSE: ABBV) to evaluate SpringWorks’ nirogacestat combination with ABBV-383 in relapsed or refractory multiple myeloma. Gamma secretase inhibition helps prevent the cleavage and shedding of BCMA from the surface of myeloma cells.
GlobeNewsWire
SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Tuesday Sep 07 2021 at 06:30
STAMFORD, Conn., Sept. 07, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in the H.C. Wainwright 23rd Annual Global Investment Conference. A webcast of the company presentation will be available on-demand starting Monday, September 13, 2021 at 7:00 am ET.
GlobeNewsWire
SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
Monday Aug 30 2021 at 06:30
— Research to be Led by Constantine Mitsiades, M.D., Ph.D., at Dana-Farber Cancer Institute — — Research to be Led by Constantine Mitsiades, M.D., Ph.D., at Dana-Farber Cancer Institute —
Zacks Investment Research
New Strong Sell Stocks for August 13th
Friday Aug 13 2021 at 11:38
LASR, TWLO, SWTX, FSLY, and UUUU have been added to the Zacks Rank #5 (Strong Sell) List on August 13, 2021
GlobeNewsWire
SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Wednesday Aug 04 2021 at 06:30
– Entered into Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA and Dosed First Patients in Three Phase 1 Clinical Trials Evaluating Nirogacestat in Combination with BCMA Therapies Across Modalities in Patients with Relapsed or Refractory Multiple Myeloma –
GlobeNewsWire
SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations
Tuesday Aug 03 2021 at 06:30
Platform Study to Evaluate Mirdametinib as a Combination Therapy with Fulvestrant in Patients with ER+ Metastatic Breast Cancer and as a Monotherapy in Patients with Advanced Solid Tumors Harboring Activating Mutations in MEK1 or MEK2 Platform Study to Evaluate Mirdametinib as a Combination Therapy with Fulvestrant in Patients with ER+ Metastatic Breast Cancer and as a Monotherapy in Patients with Advanced Solid Tumors Harboring Activating Mutations in MEK1 or MEK2
GlobeNewsWire
SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041
Tuesday Jul 20 2021 at 07:30
STAMFORD, Conn., July 20, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,066,358 (the ‘358 patent), directed to mirdametinib, the Company’s product candidate in development for several oncology indications, including as a monotherapy for patients with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN). The ‘358 patent, assigned to Warner-Lambert Company LLC (a subsidiary of Pfizer), expires in 2041. The ‘358 patent is a composition of matter patent that covers the polymorphic form of mirdametinib that is currently in clinical development. SpringWorks has exclusive rights to the ‘358 patent pursuant to an existing worldwide license with Pfizer.
InvestorPlace
7 Top-Rated Pharmaceutical Companies to Invest In for July
Friday Jul 09 2021 at 09:15
Pharma stocks like MNMD stock and ANVS stock offer investors long-term growth potential in a market on track to hit a value of $1.70 trillion. The post 7 Top-Rated Pharmaceutical Companies to Invest In for July appeared first on InvestorPlace.
Benzinga
SpringWorks Therapeutics Reveals Updated Interim Mirdametinib Data In Rare Genetic Disorder
Wednesday Jun 16 2021 at 06:40
SpringWorks Therapeutics Inc (NASDAQ: SWTX) announced an update on the previously reported interim data from the first 20 adult patients enrolled in Phase 2b ReNeu trial evaluating mirdametinib for NF1-associated plexiform neurofibromas (NF1-PN), Data were presented at the 2021 Children’s Tumor Foundation NF Conference.
GlobeNewsWire
SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma
Wednesday Jun 16 2021 at 06:30
STAMFORD, Conn., June 16, 2021 (GLOBE NEWSWIRE) — SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported the initiation of a Phase 1/2 clinical trial to evaluate mirdametinib, an investigational MEK inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma (LGG). The study is sponsored by St. Jude Children’s Research Hospital. More information on the trial can be found on http://www.clinicaltrials.gov under the identifier NCT04923126.
SpringWorks Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
SpringWorks Therapeutics’s Altman Z-score is 13.45 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
SpringWorks Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $70.88K of common stock in SpringWorks Therapeutics on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
SpringWorks Therapeutics’s Income Quality of 0.39 is lower than its Industry Group of 0.69 (-43.5% lower)
SpringWorks Therapeutics’s Income Quality of 0.39 is lower than its Major Industry Group of 0.71 (-45.1% lower)
SpringWorks Therapeutics’s Income Quality of 0.39 is lower than its Sector of 0.75 (-48.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
SpringWorks Therapeutics’s Current Ratio of 11.55 is greater than its Industry Group of 4.76 (142.6% greater)
SpringWorks Therapeutics’s Current Ratio of 11.55 is greater than its Major Industry Group of 4.32 (167.4% greater)
SpringWorks Therapeutics’s Current Ratio of 11.55 is greater than its Sector of 2.6 (344.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-6.17 & -1.27)
Cannot compare a negative PE Ratio (-6.17 & -1.1)
Cannot compare a negative PE Ratio (-6.17 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
SpringWorks Therapeutics’s PB Ratio of 3.94 is greater than its Industry Group of 1.34 (194.0% greater)
SpringWorks Therapeutics’s PB Ratio of 3.94 is greater than its Major Industry Group of 1.4 (181.4% greater)
SpringWorks Therapeutics’s PB Ratio of 3.94 is greater than its Sector of 1.62 (143.2% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
SpringWorks Therapeutics’s ROE of -0.64 is lower than its Industry Group of -0.44 (-45.5% lower)
SpringWorks Therapeutics’s ROE of -0.64 is lower than its Major Industry Group of -0.38 (-68.4% lower)
SpringWorks Therapeutics’s ROE of -0.64 is lower than its Sector of -0.03 (-2033.3% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
SpringWorks Therapeutics’s ROCE of -0.65 is lower than its Industry Group of -0.42 (-54.8% lower)
SpringWorks Therapeutics’s ROCE of -0.65 is lower than its Major Industry Group of -0.37 (-75.7% lower)
SpringWorks Therapeutics’s ROCE of -0.65 is lower than its Sector of -0.04 (-1525.0% lower)
Derived from SEC.GOV filing dataopen_in_new